Singapore, May 28 -- Japan-based Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute. This modality enables precise control over the drug-to-antibody ratio and attachment site of single- and dual-payload ADCs, representing a major breakthrough toward more effective and safer use in a broad range of therapies.

ADCs are an advanced form of targeted biologics treatment that combines the precision of an antibody with the potency of a cell-killing payload. Compared to conventional treatments, bioconjugation with ADCs more selectively targets cancer cells while minimizing damage to surrounding cells. Drawing from its long-standing research into carbohydrates a...